






Spectrum Pharmaceuticals, Inc.  
Investor Relations Department  
157 Technology Drive  
Irvine, CA 92618  
United States

Visit IR website   
Sign-up for email alerts 

**NASDAQ: SPPI** <sup>1</sup>

Last Trade:	9.50
Trade Time:	4:00 PM ET Aug 16, 2017
Change:	0.12  (1.279%)
Day Range	9.20 - 9.60
52-Week Range	3.21 - 9.70
Volume	745,893
Market Cap. (\$M)	802.750
Shares Out (M)	84.500

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncology and Hematology. The Company's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy.

Spectrum Pharmaceuticals' stock is traded through the Nasdaq Global Market System.

Ticker Symbol: [SPPI](#)

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Aug 14, 2017  
[Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ \(apaziquone\) in Patients with Non-Muscle Invasive Bladder Cancer \(NMIBC\)](#)

Aug 3, 2017  
[Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update](#)

Aug 1, 2017  
[Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study \(ADVANCE\) of ROLONTIS™ \(eflapregrastim\), a Novel Long-Acting GCSF](#)

Jul 27, 2017  
[Spectrum Pharmaceuticals Announces Second Quarter 2017 Financial Results Teleconference and Webcast](#)

Jun 19, 2017  
[Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® \(pralatrexate injection\) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma \(14-ICML\) Meeting](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Second Quarter Financial Results](#)

Mar 14, 2017  
[Annual Report \(10-K\)](#)

Apr 17, 2017  
[Definitive Proxy Statement](#)

Aug 4, 2017  
[Quarterly Report \(10-Q\)](#)

May 4, 2017  
[Quarterly Report \(10-Q\)](#)

Nov 14, 2016  
[Quarterly Report \(10-Q\)](#)

